SUPERNUS PHARMACEUTICALS, INC. 4

Jack A. Khattar (President, CEO of Supernus Pharmaceuticals, Inc.) received 29,849 shares of common stock upon vesting of performance share units on 2026-07-29.

On July 29, 2026, Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, Inc., acquired 29,849 shares of common stock through the vesting of previously granted Performance Share Units, following the achievement of specified individual performance objectives. The shares were acquired at no cash cost to the insider as part of an equity incentive compensation arrangement, and his direct ownership increased by 29,849 shares accordingly. The filing notes that the performance share units were originally awarded on February 19, 2025, with objectives established on May 3, 2025, and this transaction reflects routine incentive compensation vesting rather than an open-market purchase or sale.

Filing Facts

CIK

1356576

Ticker

SUPN

Form

4

Source Type

fda

Accession

0001539937-26-000010

Alert Tier

5